Preclinical pharmacology of amphetamine: Implications for the treatment of neuropsychiatric disorders

• Published in: Pharmacology & therapeutics (Oxford) Vol. 143; no. 3; pp. 253 - 264
• Main Authors: Hutson, Peter H., Tarazi, Frank I., Madhoo, Manisha, Slawecki, Craig, Patkar, Ashwin A.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier 01.09.2014
• Subjects: Amphetamine - pharmacology; Amphetamine - therapeutic use; Animals; Biogenic Amines - metabolism; Biological and medical sciences; Glutamic Acid - metabolism; Humans; Lens diseases; Medical sciences; Mental Disorders - drug therapy; Mental Disorders - metabolism; Ophthalmology; Opioid Peptides - metabolism; Receptor, Cannabinoid, CB1 - metabolism; Receptor, Cannabinoid, CB2 - metabolism; Synaptic Transmission - drug effects; Amphetamine derivatives; CNS stimulant; Psychotropic; Preclinical trial; Monoamine; Opiates; Pharmacology; Cannabinoid; Glutamate; Monoamines; Endogenous; Treatment; Amphetamine; Endocannabinoid; Excitatory aminoacid; Neurotransmitter; Mental disorder; Amfetamine; Endogenous opioids; Endocannabinoids

The primary mechanism by which amphetamine exerts its neurobehavioral effects is through an enhancement of synaptic monoamine levels, which is mediated by interactions with monoamine transporters, storage, and metabolism. However, preclinical data are now emerging that support more widespread neurob...